Integrating genetic and pharmacological approaches in vitro and in vivo we demonstrate that the pro-invasive activity of LPA on triple negative breast cancer cells depends on an LPA1/PI3K/ZEB1/miR-21 activation cascade. The gene discussed is ZEB1; the disease is triple-negative breast carcinoma.